Showing results (141-150 of 170) with videos related to

Sort By:
Pageof 17
JCI Insight|May 11, 2021
Urinary EGF and MCP-1 and risk of CKD after cardiac surgerySteven Menez, Wenjun Ju, Rajasree Menon, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 16, 2020
Systematic Review and Meta-Analysis of Native Kidney Biopsy ComplicationsEmilio D Poggio, Robyn L McClelland, Kristina N Blank, et al.
Glomerular Diseases|October 30, 2023
CureGN-Diabetes Study: Rationale, Design, and Methods of a Prospective Observational Study of Glomerular Disease Patients with DiabetesAmy K Mottl, Andrew S Bomback, Laura H Mariani, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 8, 2024
C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after TransplantationBlanca Tarragón, Yonatan Peleg, Geetha Jagannathan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 1, 2023
Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy StudyChia-Shi Wang, Dorey A Glenn, Margaret Helmuth, et al.
Kidney Medicine|May 14, 2024
Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two CasesVíctor J Escudero-Saiz, Ángela Gonzalez, Adriana García-Herrera, et al.
American Journal of Nephrology|November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor DanicopanSteven D Podos, Howard Trachtman, Gerald B Appel, et al.
Kidney International|October 6, 2018
Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allograftsDominick Santoriello, Syed A Husain, Sacha A De Serres, et al.
American Journal of Nephrology|November 24, 2022
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 StudiesCarla Nester, Gerald B Appel, Andrew S Bomback, et al.
Kidney International Reports|December 18, 2019
Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN)Michelle M O'Shaughnessy, Jonathan P Troost, Andrew S Bomback, et al.
Pageof 17